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Aims Female sex and sex hormones contribute to cardiac remodelling. 17b-estradiol (E2) is involved in the modulation of
extracellular matrix composition and function. Here, we analysed the effect of E2 on matrix metalloproteinase
(MMP)-2 gene expression and studied the underlying molecular mechanisms in rat cardiac ﬁbroblasts and in a
human ﬁbroblast cell line.
Methods
and results
In adult rat cardiac ﬁbroblasts, E2 signiﬁcantly decreased MMP-2 gene expression in an estrogen receptor (ER)-
dependent manner. Transient transfection experiments of human MMP-2 (hMMP-2) promoter deletion constructs
in a human ﬁbroblast cell line revealed a regulatory region between 2324 and 2260 bp that is involved in E2/
ERa-mediated repression of hMMP-2 gene transcription. Electrophoretic mobility shift assays (EMSA) and supershift
analysis demonstrated the binding of transcription factor Elk-1 within this promoter region. Elk-1 was phosphorylated
by E2 via the mitogen-activated protein kinase (MAPK) signalling pathway as shown by western blotting. Treatment of
cells with the MAPK inhibitor PD98059 blocked the E2-dependent repression of hMMP-2 promoter activity as well as
the endogenous MMP-2 mRNA levels in both human ﬁbroblast cells and rat cardiac ﬁbroblasts.
Conclusion E2 inhibits MMP-2 expression via the ER and the MAPK pathway in rat cardiac ﬁbroblasts and in a human ﬁbroblast
cell line. These mechanisms may contribute to sex-speciﬁc differences in ﬁbrotic processes that are observed in
human heart and other diseases.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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1. Introduction
The regulation of the extracellular matrix (ECM) by matrix metal-
loproteinases (MMPs) and tissue inhibitors of metalloproteinases
(TIMPs) contributes to the structural and functional integrity of
the heart.
1 MMPs are a family of zinc-dependent enzymes that
are mainly synthesized by cardiac ﬁbroblasts and involved in per-
manent matrix turnover.
2 Alterations in MMP expression and
activity contribute to the development of depressed cardiac
function, progression of cardiac failure, and increased mortality in
animal models and humans.
3
MMP-2(gelatinase A)plays a dominantrole incardiac remodelling.
Increased MMP-2 expression and activityoccurs after aortic stenosis,
myocardialinfarction(MI),duringleftventricularhypertrophy,inheart
failure and is associated with adverse cardiac remodelling.
4–8Consti-
tutive cardiac-speciﬁc MMP-2 expression in transgenic mice induced
sever ventricular remodelling and systolic dysfunction.
9 In contrast,
the inhibition or targeted deletion of MMP-2 in animal models
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doi:10.1093/cvr/cvp350attenuated the progression of left ventricular remodelling and
improved the survival after MI or pressure overload.
10–12 Thus,
MMP-2 is directly involved in pathological ventricular remodelling.
Male mice subjected to transverse aortic constriction-induced
pressure overload exhibit a higher MMP-2 mRNA expression
than female mice.
13 A higher MMP-2 activity was also observed
in male mice after MI with corresponding remodelling compared
with female mice.
14 The sex hormone 17b-estradiol (E2) is a
possible candidate that could be responsible for these sex
differences.
MMP-2 expression is controlled at the transcriptional level by
cytokines, hormones, and growth factors via induction or suppres-
sion of promoter activity.
8,15,16 E2 regulates MMP-2 gene
expression in a cell- and tissue-speciﬁc manner. E2 treatment
leads to an up-regulation of MMP-2 gene expression in isolated
mice mesangial cells, human vascular smooth muscle cells, and in
human retinal pigment epithelium
17–19 and to a down-regulation
of MMP-2 expression in MCF-7 cells, isolated human pelvic ﬂoor
ﬁbroblasts, and prostate cancer cells.
20–22 However, currently
little is known about the molecular mechanisms regulating the
MMP-2 gene expression by E2.
The effects of E2 are mainly mediated by two estrogen receptors
(ER), ER alpha (a) and ER beta (b), which belong to the superfamily
ofnuclear receptors.
23 Althoughthe presenceofbothfunctionalER
in cardiac ﬁbroblasts obtained from male and female rats has been
reported,
24 it is not evident whether E2-activated ER have the
same effects on the regulation of gene expression in both sexes.
Therefore, in the present study, we analyse the effect of E2 on the
MMP-2 gene expression in cardiac ﬁbroblasts isolated from adult
female and male rats. Furthermore, we elucidated the molecular
mechanisms involved in E2-mediated regulation of the human
MMP-2 gene expression in a human ﬁbrosarcoma cell line and con-
ﬁrmedtheregulatorypathwayinratcardiacﬁbroblasts.Theelucida-
tionoftheeffectofE2ontheregulationofMMP-2geneexpressionin
ﬁbroblastscouldhelpunderstandsexdifferencesincardiacremodel-
ling and improve therapeutic approaches for cardiac remodelling
after MI and pressure overload.
2. Methods
2.1 Cell culture
Cardiac ﬁbroblasts from adult female and male Wistar rats (9–11
weeks) were prepared by enzymatic digestion (collagenase, dispase,
and trypsin) as described earlier.
25 These investigations were approved
by the Landesamt fu ¨r Gesundheit und Soziales (LaGeSo, Berlin, Germany)
for the use of laboratory animals (O0006/05) and conform to the
Guide for the Care and Use of Laboratory Animals published by the US
National Institutes of health (NIH Publication No. 85-23, revised
1996). Purity of cardiac ﬁbroblasts was determined by morphological
characterization and immunostaining [positive: with anti-Vimentin anti-
body (Oncogene) and negative: von Willebrand factor VIII (Dako)].
Human ﬁbrosarcoma cell line (HT1080 cells, CCL-121), derived
from a ﬁbrosarcoma in a 35-year-old male in 1972,
26 was bought
from German Collection of Microorganisms and Cell Culture
(DSMZ, Braunschweig, Germany).
Cardiac Fibroblasts and HT1080 cells were cultured in Dulbecco’s
modiﬁed Eagles medium (DMEM) with phenol red and 10% foetal
bovine serum (FBS) supplemented with 1 mM HEPES, 2 mM
L-glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin at
378C under 5% CO2. For E2 treatment, cells were grown in sup-
plemented DMEM without phenol red and 10% charcoal stripped
FBS (c.s. FBS). Prior to E2 treatment, cells were starved with 2.5%
c.s. FBS in DMEM without phenol red for 24 h, subsequently incubated
with the physiological concentration of E2 (10
28 M; Sigma) or Dextrin
(Sigma) as vehicle for additional 24 h. Cells were pre-incubated with
ER-antagonist ICI 182,780 (10
25 M; Tocris) and inhibitor of
mitogen-activated protein kinase (MAPK) cascade PD98059 (10 mM;
Calbiochem) for 1 h prior to E2 treatment. Immunostaining of
cardiac ﬁbroblast treated and non-treated with E2, using anti
a-smooth muscle actin antibody (Sigma), revealed that E2 has no
effect on ﬁbroblast differentiation into myoﬁbroblasts (data not
shown).
2.2 RNA isolation and real-time polymerase
chain reaction
Total RNA isolation and real-time polymerase chain reaction (PCR)
was performed as previously described.
13 The mRNA content of
target genes was normalized to the expression of hypoxanthine phos-
phoribosyl transferase in cardiac ﬁbroblasts and to the expression of
Glycerinaldehyde-3-phosphate-Dehydrogenase (GAPDH) in HT1080
cells. Primer sequences used for ampliﬁcation are listed in Supplemen-
tary material online, Table S1).
2.3 Construction of luciferase promoter
constructs
HumangenomicDNA,isolatedfromperipheralbloodsamplesofhealthy
volunteers (n ¼ 3) by QIAamp DNA Blood kit (Qiagen), was used as a
template to amplify different fragments containing the 50-ﬂanking region
of the hMMP-2 gene by PCR. The investigation conforms with the prin-
ciples outlined in the Declaration of Helsinki for investigations involving
human subjects
27 and has been approved by the ethics commission of
the university Witten/Herdecke e.V. (04/2004). Primer sequences
used for ampliﬁcation are displayed in Supplementary material online,
Table S2. The hMMP-2 promoter fragments (21174 bp/þ17 bp,
2960 bp/þ17 bp, 2685 bp/þ17 bp, 2685 bp/2260 bp, 2417 bp/þ
17 bp, and 2324 bp/þ17 bp, relative to the translational start site
þ1 bp)wereclonedintopCR2.1vectorusingTAcloningvectorkit(Invi-
trogen) and conﬁrmed by sequencing. Individual promoter fragments
were sub-cloned into the luciferase reporter vector pGL2-basic
(Promega) using Sac I restriction sites in sense and Hind III in antisense
orientation.
2.4 Transient transfection and dual luciferase
reporter assays
For transient-transfection experiments, HT1080 cells were plated into
12-well tissue plates and grown to approximately 70–80% conﬂuence
before being transfected. Transfection experiments were performed
using FUGENE
w6 reagent (Roche Diagnostics) according to the man-
ufacturer’s protocol. HT1080 cells were transiently transfected with
1 mg of luciferase promoter construct and 10 ng of Renilla luciferase
plasmid (phRL-TK, Promega) which was used as a standard reference
control. In co-transfection experiments, the cells were additionally
co-transfected with 500 ng human ERa (hERa)-vector (HEGO-pSG5
vector) using similar transfection procedure. Luciferase-assays were
performed using the Dual-Luciferase Reporter Assay System
(Promega) following the manufacturer’s instructions. Fireﬂy and
Renilla luciferase activities were sequentially measured in a Wallac
409 beta-counter (Berthold-Wallac). Fireﬂy luciferase activities were
S. Mahmoodzadeh et al. 720normalized based on the Renilla luciferase activity in each well. Trans-
fection experiments were carried out in triplicates for each construct
and performed independently at least three times.
2.5 Western blot analysis
HT1080cellextractwasisolatedusingdouble-detergentlysisbuffer(Sup-
plementary material online, Table S3) and separated by SDS–
polyacrylamide gel electrophoresis. Western-blotting was performed
using anti-p-Elk-1 antibody (sc-8406, Santa Cruz), anti-p-ERK1/2
(mAb#4370, Cell Signaling), anti-ERK1/2 antibody (mAb#4695, Cell Sig-
naling), anti-MMP2 antibody (M4677, Sigma), and anti-GAPDH antibody
(MAB374, Chemicon) for normalization. Speciﬁc bands were visualized
using ECLTM detection kit (GE Healthcare). Band intensities were quanti-
ﬁed with Alpha Ease FCTM (Version 3.1.2, Alpha Innotech Corporation).
2.6 Electrophoretic mobility shift assays
(EMSA) and supershift assays
Preparation of nuclear extracts from transfected HT1080 cells, treated
with E2 or vehicle, and performance of Electrophoretic mobility shift
assays (EMSA) were previously reported.
28 Brieﬂy, double-stranded
oligonucleotides corresponding to the hMMP-2 promoter sequence
from 2296 to 2256 bp (50-cctcccttgtttccgctgcatccagacttcctcaggcttc
g-30), including putative Elk-1 binding site, were end-labelled with
32P-dATP. Binding reaction mixture, including 10 mg of nuclear extracts
(E2- or vehicle-treated), end-labelled Elk-1 oligonucleotide
(60.000 cpm), 2 mg poly [d(IC)], and 1x binding buffer (Supplementary
material online, Table S4), was incubated for 1 h at room temperature.
For supershift assays, anti-Elk-1 antibody (4 mg, sc-355X, Santa Cruz)
and anti-p-Elk-1 antibody (2–6 mg, sc-8406X, Santa Cruz) were incu-
bated with nuclear extracts for 30 min at 48C before addition of
binding reaction mixture. For competition experiments, non-labelled
double stranded oligonucleotides were added to the binding reaction
mixture in 150-fold molar excess.
2.7 Statistical analysis
Results are expressed as mean+SEM of at least three independent
experiments. Graphic representations of the results are accomplished
using the software Sigma Plot version 8. Signiﬁcant differences were
established by paired Student’s t-test using SPSS 11.0 (SPSS Inc.,
Chicago, IL, USA). Probability values P   0.05 were considered statisti-
cally signiﬁcant.
3. Results
3.1 17b-Estradiol inhibits MMP-2 and
induces ER gene expression in rat cardiac
ﬁbroblasts
E2 treatment of isolated cardiac ﬁbroblasts from adult female and
male rats for 24 h signiﬁcantly decreased the expression of MMP-2
at mRNA and protein level compared with vehicle-treated cells in
both sexes (Figure 1A; P   0.05; Figure 1B; P   0.01). Pre-treatment
with the speciﬁc ER-antagonist ICI 182,780 reversed the
E2-mediated effect, indicating that E2 inhibits MMP-2 mRNA
expression through ER. Moreover, E2 treatment of rat cardiac
ﬁbroblasts signiﬁcantly increased ERa-mRNA levels compared
with vehicle-treated cells in both sexes (Figure 1C; P   0.001).
The ERb-mRNA was signiﬁcantly increased only in cardiac ﬁbro-
blasts isolated from males, but not from female rats after 24 h of
E2 treatment (Figure 1D; P   0.05). The ER-antagonist ICI
182,780 inhibited the induction of ER mRNA-levels by E2.
3.2 17b-Estradiol inhibits the
transcriptional activity of the human
MMP-2 gene in HT1080 cells
To examine the transcriptional function of the hMMP-2 promoter,
we ﬁrst tested the basal promoter activity of the 50-ﬂanking region
from 21174 to þ17 bp (relative to the translational start) of the
hMMP-2geneinHT1080cells.Luciferasereporterassaysrevealedan
increase in promoter activity with increasing length of the hMMP-2
promoter sequence and strong enhancer regions important for
basal hMMP-2 transcription, located between 2417 bp/2324 bp,
2685 bp/2417 bp, and 21174 bp/2960 bp of the hMMP-2 pro-
moter (see Supplementary material online, Figure S1). Thus, the
hMMP-2 promoter constructs are functionally active in HT1080
cells and can be used for further analysis.
To determine the effect of E2 on the hMMP-2 promoter activity,
HT1080 cells were co-transfected with the various luciferase
hMMP-2 promoter constructs along with the hERa-vector and
subsequently treated with E2. E2 treatment signiﬁcantly reduced
hMMP-2 promoter activity of about 30–40% (Figure 2A; P  
0.001). The hMMP2-685/k-pGL2 construct, which lacks the
50-UTR of the hMMP-2 promoter region, also exhibited a signiﬁ-
cant reduction of about 30% in luciferase activity after E2 treat-
ment (P   0.001). Thus, the 50-UTR region plays no critical role
in the E2-mediated reduction of hMMP-2 promoter activity.
Since the inhibitory effect of E2 is similar among the various
hMMP-2 promoter constructs, and because all constructs have
the proximal region between 2324 and 2260 bp of the
hMMP-2 promoter in common, this region is likely to mediate
the suppressive effect of E2 on hMMP-2 transcriptional activity
(Figure 3A). Pre-treatment with ICI 182,780 signiﬁcantly reversed
the effect of E2 on MMP-2 promoter activity (Figure 2B; P  
0.001), conﬁrming that ERa is necessary for mediating the inhibi-
tory effect of E2 on hMMP-2 promoter activity.
3.3 Transcription factor Elk-1 binds to
the human MMP-2 promoter
We hypothesized that the region between 2324 and 2260 bp
was responsible for the inhibitory effect of E2 on the hMMP-2 pro-
moter activity. This region contains putative binding sites for Elk-1,
c-ETS-1, NF-1, and Sp1 (Figure 3A). All four transcription factors
either interact with ERa or can be activated by E2.
29–32 No estro-
gen responsive element (ERE) is present within this region. The
incubation of the oligonucleotide spanning the putative Elk-1
binding site (2296 to 2256 bp) with nuclear extract from
E2-treated HT1080 cells resulted in a retarded DNA–protein
complex (Figure 3B). Complex formation was efﬁciently competed
by a 150-fold molar excess of non-labelled Elk-1 oligonucleotide
(Figure 3B), suggesting the presence of Elk-1 within this complex.
The addition of a speciﬁc anti-Elk-1 antibody resulted in a super-
shifted band, which was efﬁciently inhibited by an excess of non-
labelled Elk-1 oligonucleotide (Figure 3B). These ﬁndings conﬁrmed
the presence of Elk-1 in the DNA–protein complexes. However,
the incubation of nuclear extract from vehicle-treated HT1080
Effect of E2 on MMP-2 transcription 721Figure 1 Regulation of endogenous MMP-2, ERa, and ERb expression in isolated cardiac ﬁbroblasts from adult female and male rats after
17b-estradiol (10
28 M) treatment for 24 h. (A) MMP-2 mRNA-expression is signiﬁcantly down-regulated in cardiac ﬁbroblasts of both
sexes. (B) MMP-2 protein expression is also signiﬁcantly down-regulated in cardiac ﬁbroblasts of both sexes. Left panel shows a representative
western blot for MMP-2 protein from cardiac ﬁbroblasts of female and male rats treated with 17b-estradiol or vehicle; GAPDH was used as an
internal standard. Right panel shows summarized results from cardiac cells of female and male rats. (C)E R a mRNA-expression is signiﬁcantly
up-regulated in both sexes, (D) whereas ERb mRNA-expression is only signiﬁcantly induced in cardiac ﬁbroblasts from male rats. ICI 182,780
(10
25 M) inhibited the 17b-estradiol effect, indicating the involvement of ER. Relative mRNA-expression levels of 17b-estradiol treated cells are
expressed as fold induction of vehicle-treated cells. Data are means+SEM (n ¼ 4). *P   0.05, **P   0.01, ***P   0.001.
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site also resulted into a retarded DNA–protein complex
(Figure 3C). Addition of speciﬁc anti-Elk-1 antibody demonstrated
the presence of Elk-1 within the formed complex, similar to E2
treated cells (Figure 3C). These ﬁndings suggest a constitutive
binding of Elk-1 to the hMMP-2 promoter in HT1080 cells.
To understand how E2 modulates the hMMP-2 promoter
activity via Elk-1, we investigated whether or not the phosphory-
lated Elk-1 (p-Elk-1) is present in the DNA–protein complex.
Since E2 induces the phosphorylation of Elk-1 in different cell
lines and phosphorylation of Elk-1 modulates its transcriptional
activity, we performed supershift assays using anti p-Elk-1 antibody.
No supershifted band was observed. However, the intensity of
both shift bands gradually decreased with an increasing amount
of anti p-Elk-1 antibody (Figure 3D). These data suggest that
p-Elk-1 is present in the DNA–protein complexes at the
hMMP-2 promoter.
3.4 17b-Estradiol phosphorylates Elk-1
via ERK1/2 signalling
Next, we investigated whether or not the phosphorylation level of
Elk-1 in HT1080 cells is affected by E2. Treatment of HT1080 cells
with E2 showed a signiﬁcant increase in Elk-1 phosphorylation in
whole cell extract compared with the vehicle-treated cells
(Figure 4A; P   0.01). Pre-treatment with ICI 182,780 signiﬁcantly
reversed (P   0.01) the effect of E2-mediated phosphorylation of
Elk-1, indicating that Elk-1 phosphorylation by E2 in HT1080
cells is ER-dependent. The phosphorylation of Elk-1 is mainly
mediated by the activation of MAPK-ERK1/2 signalling pathway.
33
Figure 2 17b-Estradiol inhibits human MMP-2 promoter activity in HT1080 cells. Lengths of human MMP-2 promoter fragments are dis-
played by numbers (bp), referring to the translation start site (þ1 bp). Streaked bars present different promoter fragments, black bars
present the 50-UTR and grey bars present part of Exon 1 of the human MMP-2 gene. The ‘k’ marks the truncated hMMP2-promoter construct
without 50-UTR. Luciferase activities were assayed as described in Material and Methods. (A)1 7 b-Estradiol (10
28 M) signiﬁcantly inhibits luci-
ferase activity of human MMP-2 promoter constructs compared with vehicle-treated cells. Results represent luciferase activities as mean+SEM
(n ¼ 4). (B)1 7 b-Estradiol signiﬁcantly inhibited luciferase-activity of hMMP2-417-pGL2 construct. ICI 182,780 (10
25 M) signiﬁcantly reversed
the 17b-estradiol mediated inhibition of luciferase activity. Results represent luciferase activities as mean+SEM (n ¼ 3). Relative luciferase
levels of 17b-estradiol treated cells are expressed as fold induction of vehicle-treated cells. ***P   0.001,
###P   0.001.
Effect of E2 on MMP-2 transcription 723To elucidate whether E2 mediates its effect via this signalling
pathway, HT1080 cells were pre-treated with PD98059 to inhibit
activation of MAPK-ERK1/2. PD98059 signiﬁcantly reduced the
E2-mediated phosphorylation of Elk-1 (Figure 4B; P   0.05). In
summary, E2 treatment elevates phosphorylation level of Elk-1 in
HT1080 cells via activation of ER and MAPK pathway.
3.5 17b-Estradiol inhibits transcriptional
activity of the human MMP-2 promoter
via ERK1/2 signalling
To investigate whether or not E2-mediated down-regulation of the
hMMP-2 transcriptional activity is mediated by MAPK pathway,
HT1080 cells, co-transfected with hMMP2-417-pGL2 construct
and hERa-vector, were incubated with PD98059 prior to E2 treat-
ment. The inhibition of MAPK-ERK1/2 signalling pathway by
PD98059 signiﬁcantly inhibited the suppressive effect of E2
(Figure 5A; P   0.01). This experiment demonstrates that E2
mediates its inhibitory effects on the transcriptional activity of
hMMP-2 promoter through activation of MAPK-ERK1/2 pathway.
3.6 17b-Estradiol inhibits the human
MMP-2 mRNA-expression via ER and
ERK1/2
Next we analysed whether or not the endogenous hMMP-2 gene
expression in HT1080 cells is modulated by E2 and if E2 mediates
its effect by activating ER and MAPK-ERK1/2 signalling pathway. E2
treatment of HT1080 cells led to a signiﬁcantly reduced endogen-
ous hMMP-2 mRNA expression (Figure 5B; P   0.01). Pre-
treatment of the cells with ICI 182,780 and PD98059 signiﬁcantly
reversed the E2-mediated reduction of hMMP-2 mRNA expression
(P   0.001 and P   0.01, respectively). Additionally, we showed
that E2 treatment increased the phosphorylation of ERK1/2
time-dependently (Figure 5C). Taken together, these data indicate
that E2 exerts its inhibitory effect on the endogenous hMMP-2
mRNA expression by the activation of ER and MAPK-ERK1/2
Figure 3 Inhibitory effect of 17b-estradiol on the human MMP-2 promoter is mediated through the region between 2324 and 2260 bp. (A)
Regulatory region of the human MMP-2 promoter contains putative binding sites for different transcription factors. (B) EMSA and supershift
analysis with the speciﬁc Elk-1 antibody revealed the binding of the transcription factor Elk-1 to the human MMP-2 promoter region with
and (C) without 17b-estradiol-treatment (10
28 M). (D) Incubation of nuclear extracts from HT1080 cells with the speciﬁc antibody against
p-Elk-1 did not reveal a supershift, but intensities of speciﬁc shift bands decreased gradually with increasing amount of p-Elk-1 antibody. Speciﬁc
shifts and supershifts are marked with an arrow.
S. Mahmoodzadeh et al. 724pathway. Theses results support our presented data reporting the
inhibitory effect of E2 on hMMP-2 promoter activity.
3.7 17b-Estradiol inhibits MMP-2
mRNA-expression via ERK1/2 signalling
in rat cardiac ﬁbroblasts
Finally, we conﬁrmed that the inhibiting effect of E2 on MMP-2
mRNA in adult rat cardiac ﬁbroblasts is also mediated via
MAPK-ERK1/2 signalling. Pre-treatment of cardiac ﬁbroblasts
with PD98059 signiﬁcantly abolished the E2-mediated reduction
of endogenous MMP-2 mRNA-expression in both sexes
(Figure 5D; P   0.01). Taken together, these data strongly indicate
that E2 regulates MMP-2 gene expression in human ﬁbrosarcoma
cells and rat cardiac ﬁbroblasts via the same regulatory pathways.
4. Discussion
Female rodents exhibit less pro-ﬁbrotic remodelling than males
when exposed to MI or pressure overload; however, the mechan-
isms are not yet understood. This study is the ﬁrst to show the
inhibitory effect of E2 on MMP-2 gene expression via ER and
MAPK-ERK1/2 signalling in adult rat cardiac ﬁbroblasts. Further-
more, we show that E2 mediates its effect through a deﬁned
region within the hMMP-2 promoter, which binds the transcription
factor Elk-1. Phosphorylation of Elk-1 by E2 was also mediated via
ER and MAPK pathway, suggesting Elk-1 as a mediator of
E2-induced down-regulation of MMP-2 gene expression in ﬁbro-
blast cells.
To understand sex differences in cardiac remodelling, we ana-
lysed the regulation of MMP-2 gene expression by E2. Sex differ-
ences in response to E2 have been observed in different cell
types. In human adenocarcinoma cell lines from women and
men, E2 stimulated proliferation and transcription of an E2
response element-driven reporter gene only in cells from
women, but not men.
34 This was due to the differential sex-speciﬁc
activation of ER without differences in the protein expression level
of both receptors. In rat cardiac ﬁbroblasts from male and female
hearts, E2 differentially regulated the proliferative response to
hypoxia via ER-dependent pathways.
35 The E2 effect on MMP-2
gene expression has not yet been directly compared in cardiac
ﬁbroblasts from male and females. We found that E2 has the
same inhibitory effect on the MMP-2 gene expression in cardiac
ﬁbroblasts from adult female and male rats. Using the speciﬁc
ER-antagonist ICI 182,780, we obtained evidence that the E2
effect was mediated by ER in both sexes.
Both, ERa and ERb, are expressed in female and male hearts of
humans and rodents.
24,36,37 Gene expression proﬁling and cluster
analysis in the mouse aorta revealed that ERa, in contrast to
ERb, plays a critical role in the E2-induced regulation of ECM
associated genes.
38 Furthermore, E2-induced transcriptional
activity of MMP-13 and MMP-1 promoter is regulated by
ERa,
39,40 supporting that ERa acts as a key driver for estrogenic
effects on MMP expression. In this study, parallel to the
Figure 4 17b-Estradiol mediates Elk-1 phosphorylation in HT1080 cells via ER and activated MAP Kinase-ERK1/2 signalling pathway. HT1080
cells were transiently transfected with hERa-vector and analysed after 24 h of treatment with Dextrin (vehicle), 17b-estradiol (10
28 M), ICI
182,780 (10
25 M) and PD98059 (10 mM) by immunoblotting using anti p-Elk-1 antibody. (A and B)1 7 b-Estradiol signiﬁcantly increased
phosphorylation-status of Elk-1 in HT1080 cells, whereas ICI 182,780 and PD98059 signiﬁcantly inhibited E2-mediated Elk-1 phosphorylation.
Membranes were subsequently re-probed with a speciﬁc GAPDH antibody as internal standard. Protein-expression levels of cells treated with
17b-estradiol, ICI 182,780 and PD98059 are expressed as fold induction of vehicle-treated cells. Bars represent means+SEM (n ¼ 3).
**P   0.01,
##P   0.01,
#P   0.05.
Effect of E2 on MMP-2 transcription 725E2-mediated down-regulation of MMP-2 gene expression in cardiac
ﬁbroblasts, we show an up-regulation of ERa-mRNA, but not
ERb-mRNA expression in cells of both sexes. These ﬁndings
suggest that ERa, rather than ERb is involved in MMP-2 gene regu-
lation in cardiac ﬁbroblasts and we therefore focused our exper-
iments on the effects of ERa.
E2 treatment of cultured human pelvic ﬂoor ﬁbroblasts, breast
cancer, and prostate cancer cells led to a down-regulation of
MMP-2 expression.
21,22,41 These studies, however, did not identify
any regulatory cis- and trans-acting elements required for mediating
the inhibitory effect of E2 on the MMP-2 expression. In the current
study, we characterized an E2-responsive region within the
hMMP-2 promoter, from 2324 to 2260 bp, with putative
binding sites for several transcription factors including Elk-1. In
line with previous reports,
30,42 E2 increased the phosphorylation
of Elk-1 through activation of ERa in HT1080 cells. Since in our
experiments Elk-1 bound, with and without E2 treatment, within
the DNA–protein complex at the hMMP-2 promoter, the phos-
phorylation of Elk-1 by E2 was considered to mediate the
E2-induced down-regulation of the hMMP-2 promoter activity.
Similar ﬁndings, whereas phosphorylation of Elk-1 down-regulated
c-fos promoter activity in a human embryonic kidney cell line and
Figure 5 Inhibitory effect of 17b-estradiol on MMP-2 transcriptional activity is mediated via ER and MAP Kinase-ERK1/2 signalling pathway in
HT1080 cells and rat cardiac ﬁbroblasts. (A) HT1080 cells were transiently co-transfected with the hMMP2-417-promoter construct and hERa
vector. PD98059 (10 mM) signiﬁcantly reversed the 17b-estradiol-dependent (10
28 M) repression of human MMP-2 promoter activity. Relative
luciferase activity of 17b-estradiol and PD98059 treated cells are expressed as fold induction of vehicle-treated cells. Luciferase activities are
means+SEM (n ¼ 4). (B) Signiﬁcant down-regulation of endogenous human MMP-2 mRNA expression by 17b-estradiol in HT1080 cells was
signiﬁcantly inhibited by ICI 182,780 (10
25 M) and PD98059 (10 mM) (n ¼ 3). (C)1 7 b-Estradiol induced phosphorylation of ERK1/2 in HT1080
cells. Membranes were subsequently re-probed with a speciﬁc ERK1/2 antibody. Western blots are representatives of three independent exper-
iments (n ¼ 3). (D) Signiﬁcant reduction of endogenous MMP-2 mRNA-levels in cardiac ﬁbroblasts of both sexes was signiﬁcantly inhibited by
PD98059 (n ¼ 4). The mRNA-expression level of 17b-estradiol, ICI 182,780 and PD98059 treated cells are expressed as fold induction of
vehicle-treated cells. Data are means+SEM. ***P   0.001,
###P   0.001 and **P   0.01,
##P   0.01,
§§P   0.01.
S. Mahmoodzadeh et al. 726primary rat embryo ﬁbroblasts, were previously reported.
43,44 The
gradual decrease of the speciﬁc nuclear protein binding to the
promoter-region, in the presence of p-Elk-1 antibody, suggests
the presence of p-Elk-1 in the DNA–protein complexes on the
hMMP-2 promoter. The failure to detect the binding of p-Elk-1
to the hMMP-2 promoter after E2 treatment may be caused by
a low amount of phosphorylation or instability of p-Elk-1. This
may lead to p-Elk-1 protein concentrations, which are insufﬁcient
to obtain a super-shift signal.
Elk-1 can be phosphorylated by E2 activated MAPK-ERK1/2
signalling pathway in MCF-7 cells.
30 E2-activated ERK1/2 in
HT1080 cells also mediated Elk-1 phosphorylation in our
study. Additionally, the inhibition of ERK1/2 pathway abolished
the inhibitory effect of E2 on hMMP-2 promoter activity, indicat-
ing that MAPK-ERK1/2 pathway mediates the E2-dependent
transcriptional repression of the hMMP-2 promoter in HT1080
cells. This regulatory mechanism is not only limited to the trans-
fected hMMP-2 promoter, but also applies to the E2-mediated
reduction of endogenous MMP-2 mRNA-expression in
HT1080 cells as well as in adult rat cardiac ﬁbroblasts of both
sexes.
Based on our results, we propose that upon E2 treatment, E2
activates the cytosolic ERa, which in turn activates the cytosolic
signal transduction cascades ras/raf, MEK1/2, and ERK1/2
(Figure 6). Activated ERK1/2 translocates into the nucleus
45
where it phosphorylates the transcription factor Elk-1.
43,44 The
binding of phosphorylated Elk-1 promotes the recruitment of
co-repressors.
46 Yang et al.
44 and Kukushkin et al.
43 showed that
the down-regulation of the c-fos promoter activity occurs
through Elk-1 phosphorylation and subsequent recruitment of
co-suppressor complex Sin3A/HDAC-1. Conceivably, a similar
mechanism could be responsible for the inhibition of hMMP-2 pro-
moter activity after E2 treatment in ﬁbroblasts.
In summary, we report the signiﬁcant down-regulation of
MMP-2 by E2 in adult cardiac ﬁbroblasts of both sexes. Moreover,
we present a novel mechanism for the E2-mediated inhibition of
MMP-2 gene expression that is active in a human ﬁbroblast cell
line and in rat cardiac ﬁbroblasts. These ﬁndings may explain
how E2 could account for an attenuated adverse remodelling by
down-regulating MMP-2 expression. This may contribute to the
understanding of the more beneﬁcial remodelling in female
hearts vs. male hearts under stress conditions.
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